Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo.
Osteoprotegerin (OPG) is a secreted member of the tumor necrosis factor (TNF) receptor superfamily that binds to the ligand for receptor activator of nuclear factor κB (RANKL) and inhibits bone resorption. OPG can also bind and inhibit the activity of the TNF-related apoptosis-inducing ligand (Apo2L/TRAIL), raising the possibility that the anticancer efficacy of soluble Apo2L/TRAIL may be abrogated in the bone microenvironment where OPG expression is high. In this study we used a murine model of breast cancer growth in bone to evaluate the efficacy of recombinant soluble Apo2L/TRAIL against intratibial tumors that were engineered to overexpress native full-length human OPG. In vitro, OPG-overexpressing breast cancer cells were protected from Apo2L/TRAIL-induced apoptosis, an effect that was reversed with the addition of soluble RANKL or neutralizing antibodies to OPG. In vivo, mice injected intratibially with cells containing the empty vector developed large osteolytic lesions. In contrast, OPG overexpression preserved the integrity of bone and prevented breast cancer-induced bone destruction. This effect was due primarily to the complete absence of osteoclasts in the tibias of mice inoculated with OPG-transfected cells, confirming the biologic activity of the transfected OPG in vivo. Despite the secretion of supraphysiologic levels of OPG, treatment with Apo2L/TRAIL resulted in strong growth inhibition of both empty vector and OPG-overexpressing intratibial tumors. While Apo2L/TRAIL-induced apoptosis may be abrogated in vitro by OPG overexpression, the in vivo anticancer efficacy of recombinant soluble Apo2L/TRAIL is retained in the bone microenvironment even in the presence of biologically active OPG at supraphysiologic concentrations.
Zinonos
Irene
I
Discipline of Orthopaedics and Trauma, Adelaide Cancer Research Institute, University of Adelaide, Adelaide, South Australia, Australia.
Labrinidis
Agatha
A
Lee
Michelle
M
Liapis
Vasilios
V
Hay
Shelley
S
Ponomarev
Vladimir
V
Diamond
Peter
P
Findlay
David M
DM
Zannettino
Andrew C W
AC
Evdokiou
Andreas
A
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D001859:Bone Neoplasms / Q000188:drug therapy / Q000473:pathology; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology; D045744:Cell Line, Tumor; D019610:Cytoprotection / Q000187:drug effects; D005260:Female; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D053244:Osteoprotegerin / Q000378:metabolism*; D012995:Solubility / Q000187:drug effects; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000494:pharmacology* / Q000627:therapeutic use; D013977:Tibia / Q000187:drug effects / Q000473:pathology; D014162:Transfection; D016896:Treatment Outcome; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; D053244:Osteoprotegerin; D053221:TNF-Related Apoptosis-Inducing Ligand
J Biol Chem. 2000 Jul 28;275(30):23319-25
10770955
Cell. 1997 Apr 18;89(2):309-19
9108485
Cancer Res. 2002 Mar 15;62(6):1619-23
11912131
Eur J Nucl Med Mol Imaging. 2004 May;31(5):740-51
15014901
J Biol Chem. 2007 Oct 26;282(43):31601-9
17702740
Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1754-9
10677530
Clin Cancer Res. 2009 May 15;15(10):3451-61
19401351
Int J Cancer. 2006 Aug 15;119(4):944-54
16550602
J Pharmacol Exp Ther. 2001 Oct;299(1):31-8
11561060
J Bone Miner Res. 2004 Oct;19(10):1712-21
15355567
Cancer Lett. 2009 Jan 18;273(2):177-93
18632203
Cancer Res. 2006 May 15;66(10):5363-70
16707463
Nat Rev Cancer. 2002 Jun;2(6):420-30
12189384
J Bone Miner Res. 2009 Jul;24(7):1150-61
19335218
J Biol Chem. 1998 Jun 5;273(23):14363-7
9603945
Blood. 2001 Aug 1;98(3):795-804
11468181
Br J Cancer. 2003 Jul 7;89(1):206-14
12838325
Apoptosis. 2005 Jan;10(1):35-51
15711921
J Clin Invest. 1999 Jul;104(2):155-62
10411544
Cancer Res. 1999 Dec 15;59(24):6153-8
10626806
Nat Med. 1999 Feb;5(2):157-63
9930862
Breast Cancer Res Treat. 2004 Aug;86(3):269-79
15567943
Bone. 2002 Oct;31(4):448-56
12398939
Cancer Res. 2004 Jul 15;64(14):4900-5
15256461
Int J Cancer. 2010 Jul 15;127(2):345-54
19924813
Int J Oncol. 2001 Sep;19(3):625-32
11494046
J Immunol. 1996 Jan 15;156(2):611-20
8543812
Cancer Res. 2003 Mar 1;63(5):912-6
12615702
Biochem Biophys Res Commun. 1997 May 8;234(1):137-42
9168977
Clin Cancer Res. 2002 Jul;8(7):2306-10
12114435